Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck to Eliminate Nearly 500 Jobs in Early 2020 Due to Shifting R&D Focus

Merck will slash about 500 jobs in early 2020 at two Montgomery County, Pa., facilities as well as in some other states, Pennsylvania’s Morning Call reported.

Read More »

Tocagen Cuts 65 Percent of Employees

Less than a month after the company’s Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a restructuring and will reduce the employee workforce by 65 percent.

Read More »

Acer Restructures, Eliminates 29 Employees

Two weeks after the U.S. FDA rejected Acer Therapeutics’ New Drug Application for Edsivo (celiprolol), the company initiated a restructuring plan that includes the elimination of 29 employees.

Read More »

ImmunoGen Culls 220 Employees

ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.

Read More »

Merrimack to Lay Off Remaining Execs and Staff, Sell Assets

Merrimack Pharmaceuticals will lay off the Cambridge, Mass.-based company’s entire staff, including the leadership team.

Read More »

Dynavax to Lay Off 37 Percent of Staff, CEO to Retire

Dynavax CEO Eddie Gray will step down from his role on Aug. 1, 2019, as the Bay Area company undergoes restructuring to move away from immuno-oncology and prioritize the vaccine business.

Read More »

Merrimack Scraps Solid Tumor Asset

Shares of Merrimack Pharmaceuticals sunk after the company announced the discontinued development of an experimental solid tumor treatment and will lay off some employees.

Read More »

Roche, Forma Cutting Jobs in Massachusetts

More than 100 Boston-area employees from two pharma companies are getting pink slips. Roche and Forma Therapeutics filed WARN notices with the state of Massachusetts.

Read More »

ASLAN, Aduro Initiate Corporate Restructuring That Includes Significant Layoffs

ASLAN Pharmaceuticals is cutting staff and initiating a corporate restructuring and strategic prioritization of the company’s clinical development programs. Aduro Biotech will institute a “strategic reset” to focus on the company’s core strengths of the discovery and development of novel product candidates in the stimulator of interferon genes and a proliferation-inducing ligand pathways.

Read More »

Two Bay Area Companies Cut Staff to Support Strategic Growth

San Francisco-based uBiome laid off about 10 percent of the company’s staff and Dublin-based Theravance Biopharma cut 50 employees as part of a focus on the execution of strategic programs.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom